How relatively likely are other endocrinopathies when comparing different classes of ICPIs

How relatively likely are other endocrinopathies when comparing different classes of ICPIs?

Patients on PD-1 inhibitors are about twice as likely to develop hypothyroidism as patients on ipilimumab. PD-1 inhibitor therapy is about five times more likely to cause hyperthyroidism compared with PD-L1 inhibitor therapy, but hypothyroidism rates are similar. Patients on ipilimumab are about five times more likely to develop hypophysitis compared with those on PD-1 inhibitor therapy alone, but those who are on a combination of these drugs are more than twice as likely to develop hypophysitis compared with those on ipilimumab alone.

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top